BioVaxys Technology Corp. Announces Financial Offering
BioVaxys Technology Corp. (CSE:BIOV) is taking a significant step forward in its growth journey by launching a non-brokered private placement financing. This exciting initiative involves offering a minimum of 7,058,824 units of the Company at an issue price of $0.17 per unit, with the potential to raise gross proceeds of up to $1,600,000 by selling a maximum of 9,411,764 units. Each unit will include a common share and a purchase warrant, allowing investors to acquire additional shares at an exercise price of 40 cents over a two-year period.
Funding Objectives for the Offering
Innovative Pipeline Development
The funds generated from this offering will significantly bolster BioVaxys' mission to expand its organic pipeline. The company aims to explore multiple licensing opportunities and collaborate on research initiatives that align with its robust technological platform. This strategy is designed to position BioVaxys as a prime partner for targeted immunotherapy developments.
Accelerated Research and Development
In addition to pursuing partnerships, BioVaxys plans to utilize the Offering proceeds for crucial research and development projects. These include securing good laboratory practice (GLP) supplies for preclinical research, as well as advancing its peanut allergy vaccine program through rigorous proof-of-concept studies.
Engagement with Academic Institutions
A key aspect of the funding initiative is the collaboration with prestigious institutions, such as McMaster University, to conduct preclinical studies related to the peanut allergy vaccine candidate. This partnership not only enhances BioVaxys' developmental capabilities but also strengthens its credibility in the research community.
Proceeds Utilization for Future Growth
With the anticipation of closing the Offering within 45 days from the announcement, the company is focused on using the proceeds to address ongoing needs in its development pipeline. Plans include filing new patents, maintaining existing patents, and conducting additional analyses of immunological data from previous studies. Each of these steps will prepare the Company for future licensing opportunities and collaboration prospects.
Regulatory and Compliance Considerations
The Offering will be conducted under the listed issuer financing exemption and is subject to several regulatory approvals, including acceptance by the Canadian Securities Exchange. Additionally, the Company may compensate eligible finders for their efforts in introducing subscribers to this exciting new opportunity.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. is dedicated to advancing patient care through innovative biopharmaceutical solutions. The company focuses on immunotherapies that leverage its unique DPX™ immune-educating technology and HapTenix© tumor cell constructs. Their current pipeline features investigational therapies targeting various cancers and immunological diseases.
BioVaxys' common shares are listed on the Canadian Securities Exchange under the symbol "BIOV", and the company also trades on the Frankfurt Bourse (FRA: 5LB). For further inquiries or detailed information, interested parties may connect with the Company through its website and social media platforms.
Frequently Asked Questions
What is the purpose of the offering by BioVaxys?
The offering is aimed to raise funds for expanding their pipeline and pursuing multiple research opportunities in immunotherapy.
How much capital is BioVaxys looking to raise?
BioVaxys aims to raise gross proceeds between $1,200,000 and $1,600,000 through the sale of its units.
What are the primary uses of the funds raised?
The funds will be used for licensing opportunities, research collaborations, production of preclinical supplies, and patent filings.
Who is BioVaxys collaborating with for research?
BioVaxys is collaborating with McMaster University for preclinical studies related to their peanut allergy vaccine.
Where can investors find more information on BioVaxys?
More information can be found on BioVaxys' official website and its profile on SEDAR+.
